Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics, Inc. is trading at $21.49, down 2.36% on the session. The 50 day average sits at $24.50 and the 200 day at $25.67, which puts the stock in a downtrend. RSI is at 48, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $19.39 with resistance near $21.85, so that band frames the current range. Average daily movement is roughly $1.50, or about 7.0% of the share price, which is what any stop placement has to allow for. The overall health score of 31 out of 100 combines a trend score of 0, momentum of 69 and a risk score of 28.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.